Status: Recruiting
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.
Participants needed: 48
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: Georgetown UniversityUpdated: Dec 24, 2025Locations: 3
Eligibility criteria
Patients must have clinical or pathologic stage I-III, histologically confirmed... [+14]
Patients who have had prior chemotherapy, radiotherapy, systemic therapy, or hor... [+7]